# Ipamorelin: Research Overview — EpiPure Peptides > A skeptic's literature summary of ipamorelin, a selective GHS-R1a growth-hormone secretagogue. Covers mechanism, the single (unsuccessful) human trial, animal pharmacology, and cited safety cautions. A ghrelin-receptor agonist whose defining feature — sparing cortisol and prolactin — is well established in animals. Its efficacy in people is not; the one placebo-controlled human trial that exists missed its primary endpoint. ## The short version Ipamorelin is a synthetic five-amino-acid peptide that activates the ghrelin receptor (GHS-R1a), the same receptor the hunger hormone ghrelin binds, triggering a pulse of growth hormone (GH) release from the pituitary gland. Its calling card in animal studies is *selectivity*: unlike older GH-releasing peptides, it does this without meaningfully raising cortisol or prolactin, even at high doses. Here is what a skeptical reading of the literature has to say up front: ipamorelin has never been approved as a drug anywhere, and it has been tested in exactly **one** placebo-controlled human trial — 114 adults recovering from bowel surgery — and that trial did not meet its primary endpoint [3]. Beyond that single study, the human data consist of an old pharmacokinetics paper in eight volunteers [4]. Everything else describing benefits — sleep, recovery, body composition — is animal data, mechanism, or unverified community report. This page keeps those categories separate and labels each one. Nothing here is a recommended dose or a claim of proven human benefit. ## What it is Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — alpha-aminoisobutyric acid (Aib) at position one, plus D-2-naphthylalanine and D-phenylalanine, substitutions chosen to resist enzymatic breakdown. It was derived from an earlier growth-hormone-releasing peptide (GHRP-1) by removing a central dipeptide, a modification that, in the original pharmacology, sharpened its selectivity for the ghrelin receptor without picking up the off-target hormonal effects of its predecessor. ## How it works Ipamorelin selectively activates GHS-R1a, the ghrelin/growth-hormone-secretagogue receptor, on pituitary somatotroph cells, triggering a discrete pulse of GH release. Population PK/PD modeling in eight healthy men found dose-proportional kinetics, a terminal half-life of roughly two hours, and a single GH pulse peaking about 40 minutes after dosing [4] — a short-acting, single-pulse profile, not a sustained elevation. Its defining pharmacological feature, established in its founding animal characterization, is that it does this without meaningfully raising ACTH, cortisol, or prolactin even at doses far above the amount needed for a GH effect — a selectivity older GH-releasing peptides such as GHRP-6 and GHRP-2 do not share. Because its GH-releasing mechanism is distinct from GHRH signaling, it is commonly paired in research and community protocols with GHRH analogues; no trial of that combination for any outcome has been published, so the popular pairing is an extrapolation from separate single-agent pharmacology, not a tested combination. ## What the research shows *The human efficacy record.* The only controlled human trial of ipamorelin (NCT00672074) tested it in 114 adults undergoing bowel resection, dosed 0.03 mg/kg intravenously twice daily for up to seven days, against placebo, for postoperative recovery. It **missed its primary endpoint**: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo — a difference that did not reach statistical significance (p=0.15) [3]. That is the single defining human study of ipamorelin's efficacy, and a rigorous reading has to say plainly that it did not demonstrate the effect it was designed to test, whatever the compound's later reputation suggests. *Human pharmacokinetics.* Separately, dosing eight healthy men with five ascending intravenous infusions established that ipamorelin's kinetics are dose-proportional, with a roughly two-hour terminal half-life and a single GH pulse about 40 minutes after dosing [4]. This tells us how the compound behaves in the body — not whether it does anything useful. *Animal pharmacology.* A 2024 ferret study found intraperitoneal ipamorelin reduced cisplatin-induced weight loss by about 24% in a chemotherapy model, but — notably — had no anti-emetic effect at all, in contrast to a related compound (anamorelin) tested in the same study, which reduced acute vomiting by 60% via a central mechanism [1]. Decades earlier, subcutaneous dosing in adult female rats produced a dose-dependent increase in longitudinal bone growth rate (42 to 52 micrometers/day) with no detectable change in circulating IGF-1 or bone-turnover markers — suggesting a partly local, GH-pulse-driven effect rather than a systemic hormonal one [5]. *The class-level safety signal.* A 28-day chronic dosing study of a *different*, structurally related GHS-R1a agonist (GSK894281, not ipamorelin itself) found dose-dependent myocardial degeneration and necrosis in rats, confirmed by histopathology and electron microscopy [2]. Ipamorelin was not the tested compound, but the finding sits on this page because it is the most relevant cardiovascular safety data that exists for anything in this receptor class — and no comparable long-duration cardiovascular study of ipamorelin itself has been published. ## Reported effects, cautions & safety *Anecdotal, not clinical evidence:* the following effects are drawn from posts and articles in research-use communities and peptide-focused blogs, not from the clinical literature above. They are unverified, the source and purity of the material used is unknown, and none of it should be read as evidence that ipamorelin does these things. The most consistently described benefit is deeper, more restorative sleep, often within one to two weeks of a pre-bed protocol, sometimes accompanied by more vivid dreams in the early weeks. Faster physical recovery and reduced post-training soreness are frequently mentioned, alongside a gradual, slow shift toward leaner body composition over weeks to months (a change confounded, by the community's own admission, with concurrent diet and training). On the adverse side, a warm facial flush or head-rush in the 5-15 minutes after injection is widely reported, along with occasional tingling or numbness in the extremities, mild water retention, increased hunger, transient dizziness or a "spacey" feeling, and localized injection-site irritation. Some long-term users describe the perceived effects fading after three to four months, which is part of the community rationale for cycling on and off. *Cited cautions, drawn from the mechanistic and animal literature:* - **Active or recent malignancy:** GH-axis stimulation raises serum IGF-1, a well-characterized growth factor; the concern that sustained GH pulses could accelerate proliferation in an existing or occult tumor is mechanistic, not derived from any observed oncologic signal in an ipamorelin study — because no such long-term study exists. - **Diabetes or insulin resistance:** GH itself reduces peripheral insulin sensitivity, and ipamorelin additionally has a GH-independent insulinotropic action on isolated pancreatic tissue in animal models — a dual effect that makes net glycemic impact in someone with existing glucose dysregulation genuinely unpredictable, with no human glycemic data to resolve it either way. - **Cardiovascular disease or heart failure:** GH excess is linked to fluid retention and cardiac enlargement, and the 28-day chronic-dosing study of a related GHS-R1a agonist found dose-dependent heart-muscle damage in rats [2] — a class-level signal, not an ipamorelin-specific finding, but one with no ipamorelin-specific long-term study to rule it out. - **Appetite or weight-related conditions:** because ipamorelin acts on the ghrelin receptor, animal work shows GH-independent stimulation of appetite and fat deposition — a mechanism that is class-typical, not unique to ipamorelin, but relevant to anyone for whom increased appetite would be unwelcome. - **Unknown long-term human safety and unverified material purity:** the entire controlled human dataset is one seven-day perioperative trial and one single-dose pharmacokinetic study — nothing addresses sustained subcutaneous self-administration over months, which is the actual pattern of research-use consumption. Research-grade ipamorelin from unregulated suppliers also carries no pharmaceutical quality assurance; purity and identity are unverified by any party this site can vouch for. ## Where it fits in Research Peptide Fundamentals Ipamorelin sits at the thinly-evidenced end of this desk. Its mechanistic selectivity — sparing cortisol and prolactin — is genuinely well characterized in animals, and that is a real pharmacological distinction from older GH-releasing peptides. But the purity-and-sourcing angle that organizes this hub applies with particular force here: a compound with one inconclusive human trial and no long-term safety data is also, not coincidentally, a compound sold entirely by research-chemical suppliers with no independent verification of what is actually in the vial. Compare that evidence picture against [tesamorelin](/tesamorelin), an approved drug with multiple large randomized trials, on the [comparison page](/compare). ![Ipamorelin research illustration — abstract GH-axis pathway motif in plum and magenta](/images/ipamorelin.webp) --- A skeptic's reading room for research-peptide literature — not a supplier, not a clinic, and never a guarantee that any vial matches its label.